Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Tecvayli Received FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma

December 2022 Vol 8 No 6

In October 2022, the FDA approved Tecvayli (teclistamab-cqyv; from Janssen Biotech), the first bispecific BCMA-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who received 4 or more previous lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.

Ajai Chari, MD
Ajai Chari, MD

“In the pivotal teclistamab [Tecvayli] study, we have continued to observe positive results in heavily pretreated patients with relapsed or refractory multiple myeloma,” said study investigator Ajai Chari, MD, Director of Clinical Research, Multiple Myeloma Program, Icahn School of Medicine, Mount Sinai, New York City. “The approval of teclistamab, as the first bispecific antibody in relapsed or refractory multiple myeloma, is a meaningful step in helping many of these hard-to-treat patients.”

The FDA approved Tecvayli based on the efficacy results of a clinical trial with 110 patients who had received 3 or more previous therapies, including a PI, an IMiD, and an anti-CD38 monoclonal antibody, and had not received BCMA-targeted therapy.

Overall, the majority (61.8%) of the patients had a response to treatment with Tecvayli. After 6 months of therapy, the estimated response to treatment was 90.6%, which was reduced to 66.5% by 9 months.

Tecvayli is associated with cytokine release syndrome, a life-threatening side effect that must be carefully monitored. The most common side effects with Tecvayli were pyrexia, cytokine release syndrome, musculoskeletal pain, injection-site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea.

Recommended For You